Discover Camcevi.
site-logo
AVAILABLE
TO ORDER
 

THE ORIGINAL CONVENIENT PREFILLED, NO-MIX SYRINGE FOR GnRH TREATMENT OF ADVANCED PROSTATE CANCER IN ADULTS

CAMCEVI® is still the first and only sub-Q leuprolide therapy in a prefilled, no-mix, ready-to-inject formulation that simplifies GnRH agonist preparation—offering consistent testosterone suppression, after the initial injection, to castrate levels from Week 4 to Week 48.1

Don’t sweat syringe prep1

Don’t SweatThe Schedule

Keep patients on schedule. Simply click or tap the dosage dial and rotate to schedule your patient’s next treatment date.*

*Recommended Dosage: 42 mg subcutaneously every 6 months.

Hand Rotator
Rotate wheel
Next Dose
02/25/24
PROVEN LEUPROLIDE EFFICACY

PROVEN
LEUPROLIDE EFFICACY

CAMCEVI offers proven leuprolide efficacy in a convenient prefilled, no-mix syringe.1

See the results
SIMPLIFIED PREPARATION

SIMPLIFIED
PREPARATION

CAMCEVI comes prefilled with no mixing required—simplifying syringe prep for you.1

Learn more about dosing
SIMPLIFIED PREPARATION

DON’T SWEAT
THE J CODE

Permanent J Code J1952 is unique to CAMCEVI and unaffected by market price changes.

View more resources and support

Don’t sweat
the coverage2,3

*As of 11/07/23.
Coverage is not indicative of
utilization management criteria.

96%

patients covered by

Medicare*

91%

patients covered by

Commercial*

Search for coverage

*As of 11/07/23.
Coverage is not indicative of
utilization management criteria.

Real stories from real people

Watch healthcare professionals talk about their experiences with CAMCEVI.*

NURSE

video-preview

Sarah L.

“Our patients have stayed at castration level so we have not had to switch a patient off of CAMCEVI.”

View more CAMCEVI testimonials.

*As with all medications, individual patient experiences may vary.

Watch now
PROVEN LEUPROLIDE EFFICACY

LIVES AND GROWING*

Patients who have undergone treatment on CAMCEVI4

*As of 08/31/2023.

Don’t sweat YOUR ORDER

Order CAMCEVI through our distribution and GPO partners.

Learn more

HAVE A QUESTION?

Let us simplify it for you.

CONNECT WITH A REPRESENTATIVE

    GET UPDATES

    Stay informed about
    CAMCEVI with regular updates,
    education, and more.

    *Required fields

    IMPORTANT SAFETY INFORMATION

    Do not use CAMCEVI® in patients with hypersensitivity to GnRH, GnRH agonist analogs, or any of the components of CAMCEVI as anaphylactic reactions to these drugs have been reported in the medical literature.

    CAMCEVI, like other GnRH agonists, causes a transient increase in serum levels of testosterone during the first week of treatment which can cause transient worsening of symptoms. As with other GnRH agonists, cases of ureteral obstruction, spinal cord compression, have been observed, which may contribute to paralysis with or without fatal complications.

    Patients with metastatic vertebral lesions and/or with urinary tract obstruction should be closely observed during the first few weeks of therapy.

    Hyperglycemia and an increased risk of developing diabetes have been reported in men receiving GnRH agonists. Blood glucose levels should be monitored and managed according to current clinical practice.

    Increased risk of myocardial infarction, sudden cardiac death, and stroke has been reported in association with the use of GnRH agonists. The risk appears low based on the reported odds ratios and should be evaluated carefully along with cardiovascular risk factors when determining a treatment for patients with prostate cancer. Patients should be monitored for cardiovascular disease and according to current clinical practice.

    Androgen deprivation therapy may prolong the QT interval. Consider periodic monitoring of electrocardiograms and electrolytes.

    Convulsions have been reported in patients receiving GnRH agonists, like CAMCEVI. Patients experiencing convulsions should be managed according to the current clinical practice.

    Monitor serum levels of testosterone following injection of CAMCEVI.

    Based on findings in animal studies and mechanism of action, CAMCEVI may cause fetal harm when administered to pregnant women.

    The most common (≥10%) adverse reactions during a median follow-up of 336 days were hot flush, hypertension, injection site reactions, upper respiratory tract infections, musculoskeletal pain, fatigue, and pain in extremity.

    INDICATION

    CAMCEVI is indicated for the treatment of adult patients with advanced prostate cancer.

    Click here for full Prescribing Information.

    References:

    1. CAMCEVI. Prescribing information. Accord BioPharma; May 2021. 2. Data on file. Accord BioPharma; 2023. 3. Data on file. Accord BioPharma; 2023. 4. Data on file. Accord BioPharma; 2023.